Peripheral Avascular Retina in Retinopathy of Prematurity - Trial NCT06044181
Access comprehensive clinical trial information for NCT06044181 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Nov 01, 2023
Nov 01, 2025
Primary Outcome
Number of eyes showing peripheral retinal active leakage.
Summary
Retinopathy of prematurity (ROP) is a widely known retinal vascular disorder in preterm
 infants and a leading cause of visual disability or blindness in children. Advances in
 antenatal care have resulted in an increase in the survival rate of infants with extremely
 low birth weight (BW). Approximately 90% of infants who develop ROP do so by a postmenstrual
 age of 46.3 weeks. In certain patients with or without treatment, the retina may fail to
 fully vascularize or may develop vascular abnormalities, thus demonstrating persistent
 avascular retina (PAR) or anomalous vessel findings at the periphery. Because of the advent
 of technologies such as ultrawide-field fluorescein angiography (UWFFA) persistent vascular
 abnormalities can be detected more readily and investigated.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06044181
Non-Device Trial